123I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial

Pediatric Blood and Cancer

Volumn 52, Issue 7, 2009, Pages 784-790

  Vik, Terry A ^a   Pfluger, Thomas ^b   Kadota, Richard ^c   Castel, Victoria ^d   Tulchinsky, Mark ^e   Farto, J C Alonso ^f   Heiba, Sherif ^g   Serafini, Aldo ^h   Tumeh, Sabah ⁱ   Khutoryansky, Natalie ^j   Jacobson, Arnold F ^j  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MUNICH   (Germany)

^c RADY CHILDREN'S HOSPITAL   (United States)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^f HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF MIAMI   (United States)

ⁱ PIEDMONT HOSPITAL   (United States)

^j GE HEALTHCARE   (United States)

more..

Author keywords

Iodine 123; mIBG; Neuroblastoma; Scintigraphy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ADREVIEW; CATECHOLAMINE; UNCLASSIFIED DRUG;

ABDOMEN; ABDOMINAL TUMOR; ADOLESCENT; ADULT; ARTICLE; CATECHOLAMINE BLOOD LEVEL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG UPTAKE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; NEUROBLASTOMA; NEUROENDOCRINE SYSTEM; PELVIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THORAX; WHOLE BODY IMAGING;

3-IODOBENZYLGUANIDINE; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEUROBLASTOMA; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SINGLE-BLIND METHOD; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YOUNG ADULT;

EID: 67650481556     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21932     Document Type: Article

References (34)

1. Wieland DM, Brown LE, Tobes MC, et al. Imaging the primate adrenal medulla with [123I] and [131I] meta-iodobenzylguanidine: Concise communication. J Nucl Med 1981;22:358-364. (Pubitemid 11143693)
2. Valk TW, Frager MS, Gross MD, et al. Spectrum of pheochromocytoma in multiple endocrine neoplasia. A. Scintigraphic portrayal using 131I-metaiodobenzylguanidine. Ann Intern Med 1981;94: 762-767.
3. Sisson JC,Wieland DM. Radiolabeled meta-iodobenzylguanidine: Pharmacology and clinical studies. Am J Physiol Imaging 1986;1: 96-103. (Pubitemid 17188385)
4. Guilloteau D, Chalon S, Baulieu JL, et al. Comparison of MIBG and monoamines uptake mechanisms: Pharmacological animal and blood platelets studies. Eur J Nucl Med 1988;14:341-344. (Pubitemid 18221176)
5. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006;36:228-247.
6. Howman-Giles R, Shaw PJ, Uren RF, et al. Neuroblastoma and other neuroendocrine tumors. Semin Nucl Med 2007;37:286-302.
7. Claudiani F, Stimamiglio P, Bertolazzi L, et al. Radioiodinated meta-iodobenzylguanidine in the diagnosis of childhood neuroblastoma. Q J Nucl Med 1995;39:21-24.
8. Feine U, Muller-Schauenburg W, Treuner J, et al. Metaiodobenzylguanidine (MIBG) labelled with 123I/131I in neuroblastoma diagnosis and follow-up treatment with a review of the diagnostic results of the International Workshop of Paediatric Oncology held in Rome, September 1986. Med Pediatr Oncol 1987;15:181-187.
9. Hadj-Djilani NL, Lebtahi NE, Delaloye AB, et al. Diagnosis and follow-up of neuroblastoma by means of iodine-123 metaiodobenzylguanidine scintigraphy and bone scan, and the influence of histology. Eur J Nucl Med 1995;22:322-329.
10. Hervas Benito I, Rivas Sanchez A, Bello Arques P, et al. Value of 123I-MIBG scanning, neuron-specific enolase and serum ferritin in the diagnosis and follow-up of patients with neuroblastoma. Rev Esp Med Nucl 2001;20:369-376. (Pubitemid 47289310)
11. Muller-Gartner HW, Erttmann R, Helmke K. Meta-iodobenzylguanidine scintigraphy in neuroblastoma - A comparison with conventional X-ray and ultrasound. Pediatr Hematol Oncol 1986; 3:97-109. (Pubitemid 17021214)
12. Okuyama C, Ushijima Y, Sugihara H, et al. 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the staging of neuroblastoma. Kaku Igaku 1998;35:835-842. (Pubitemid 29016876)
13. Okuyama C, Ushijima Y, Kubota T, et al. Utility of follow-up studies using meta-[123 I]iodobenzylguanidine scintigraphy for detecting recurrent neuroblastoma. Nucl Med Commun 2002;23: 663-672. (Pubitemid 34748006)
14. Schilling FH, Bihl H, Jacobsson H, et al. Combined (111) In-pentetreotide scintigraphy and (123)I-mIBG scintigraphy in neuroblastoma provides prognostic information. Med Paediatr Oncol 2000;35:688-691.
15. Rufini V, Fisher GA, Shulkin BL, et al. Iodine-123-MIBG imaging of neuroblastoma: Utility of SPECT and delayed imaging. J Nucl Med 1996;37:1464-1468. (Pubitemid 26321623)
16. Rufini V, Giordano A, Di Giuda D, et al. [123I]MIBG scintigraphy in neuroblastoma: A comparison between planar and SPECT imaging. Q J Nucl Med 1995;39:1-8.
17. Ishii K, Kubo A, Kusakabe K, et al. Evaluation of clinical utility of 123I-MIBG scintigraphy in localisation of tumours of sympathetic and adrenomedullary origin - A report of multicenter phase III clinical trials. [Japanese]. Kaku Igaku - Jpn J Nucl Med 2000;37: 43-59. (Pubitemid 30141242)
18. Bombardieri E, Aktolun C, Baum R, et al. 131I/123I-metaiodobenzylguandine (MIBG) scintigraphy: Procedure guidelines for tumour imaging. Eur J Nucl Med 2003;30:BP132-BP137. (Pubitemid 38017445)
19. Piepsz A, Hahn K, Roca I, et al. A radiopharmaceuticals schedule for imaging in paediatrics. Paediatrics task group European Association Nuclear Medicine. Eur J Nucl Med 1990;17:127-129.
20. SAS Institute, Inc. SAS/STAT® User's Guide 8. Cary, NC: SAS Institute; 1999. pp 1245-1246, 1259-1261, 1266-1269, 1298-1299, 1307-1308.
21. Treuner J, Feine U, Niethammer D, et al. Scintigraphic imaging of neuroblastoma with [131-I]iodobenzylguanidine. Lancet 1984;1: 333-334.
22. Kimmig B, Brandeis WE, Eisenhut M, et al. Scintigraphy of a neuroblastoma with I-131 meta-iodobenzylguanidine. J Nucl Med 1984;25:773-775.
23. Horne T, Granowska M, Dicks-Mireaux C, et al. Neuroblastoma imagedwith 23Imeta-iodo-benzylguanidine andwith 123I-labelled monoclonal antibody, UJ13A, against neural tissue. Br J Radiol 1985;58:476-480. (Pubitemid 15070147)
24. Muller-Gartner HW, Erttmann R, Helmke K. Meta-iodobenzylguanidine scintigraphy in neuroblastoma - A comparison with conventional X-ray and ultrasound. Pediatr Hematol Oncol 1986; 3:97-109. (Pubitemid 17021214)
25. CIS-US. Iobenguane [mIBG (131-I-meta-iodobenzylguanidine sulfate)]. NDA 20-084, 1994.
26. Matthay KK, Edeline V, Lumbroso J, et al. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 2003;21:2486-2491. (Pubitemid 46606329)
27. Kushner BH, Yeh SD, Kramer K, et al. Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol 2003;21:1082-1086. (Pubitemid 46594137)
28. Matthay KK, Tan JC, Villablanca JG, et al. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: A new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol 2006;24:500-506. (Pubitemid 46630470)
29. Matthay KK, Yanik G, Messina J, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131- metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 2007;25:1054-1060. (Pubitemid 46596756)
30. Lumbroso J, Guermazi F, Hartmann O, et al. Sensitivity and specificity of meta-iodobenzylguanidine (mIBG) scintigraphy in the evaluation of neuroblastoma: Analysis of 115 cases. Bull Cancer 1988;75:97-106. (Pubitemid 18050467)
31. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-1477. (Pubitemid 23228250)
32. Franzius C, Hermann K,Weckesser M, et al. Whole-body PET/CT with 11C-meta-hydroxyephedrine in tumors of the sympathetic nervous system: Feasibility study and comparison with 123I-MIBG SPECT/CT. J Nucl Med 2006;47:1635-1642. (Pubitemid 47545029)
33. Rozovsky K, Koplewitz BZ, Krausz Y, et al. Added value of SPECT/CT for correlation of MIBG scintigraphy and diagnostic CT in neuroblastoma and pheochromocytoma. AJR Am J Roentgenol 2008;190:1085-1090. (Pubitemid 351571524)
34. Giammarile F, Chiti A, Lassmann M, et al. EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging 2008;35:1039-1047.